After Hologic announced that it would sell its blood screening business to its partner Grifols for $1.85B, Stifel analyst Jonathan Block says it appears that Hologic got "an attractive price" for the unit, given the "secular pressures" that the business is facing. The analyst adds that Hologic was handicapped by its lack of ownership of the commercial channel for the blood screening, while the unit's growth rate was lower than that of the company's other businesses. Block says that the divestment was "prudent," and he keeps a $45 price target and a Buy rating on the shares.